IsoRay, Inc.

IsoRay Medical™ utilizes proprietary technologies to deliver novel brachytherapy approaches to clinicians. IsoRay’s Cesium-131 isotope has been used as primary treatment for prostate cancer in over 7,000 patients. As adjuvant radiation therapy, Cesium-131 is being employed in the management of non-small cell lung cancer, intra-cranial tumors (including meningiomas), and head & neck malignancies post-surgical resection.

More Client Stories

Former CEO, IsoRay

Dwight Babcock

isoray.com
CEO, Sonoma Pharmaceuticals

Jim Schutz

sonomapharma.com
CEO, Payment Data Systems

Louis Hoch

paymentdata.com

We help you market your investment story with maximum impact and deliver your corporate message effectively

Contact Us
or call
+1 954 360 9998